Los Angeles Capital Management
KPTI icon

Los Angeles Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Los Angeles Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,601
Closed -$307K – 1233
2024
Q2 		$307K Sell
23,601
-2,234
-9% -$37K ﹤0.01% 1005
2024
Q1 		$585K Sell
25,835
-268
-1% -$4.7K ﹤0.01% 829
2023
Q4 		$339K Buy
+26,103
New +$352K ﹤0.01% 978
2023
Q2 		– Sell
-7,582
Closed -$442K – 1228
2023
Q1 		$442K Buy
7,582
+788
+12% +$38.9K ﹤0.01% 890
2022
Q4 		$347K Buy
6,794
+1,550
+30% +$107K ﹤0.01% 998
2022
Q3 		$429K Buy
5,244
+3,999
+321% +$299K ﹤0.01% 964
2022
Q2 		$84K Hold
1,245
– – ﹤0.01% 1292
2022
Q1 		$138K Buy
+1,245
New +$155K ﹤0.01% 1377
2020
Q2 		– Sell
-974
Closed -$281K – 1491
2020
Q1 		$281K Buy
974
+165
+20% +$45.5K ﹤0.01% 1076
2019
Q4 		$233K Buy
+809
New +$176K ﹤0.01% 1173
2019
Q1 		– Sell
-4,589
Closed -$645K – 1401
2018
Q4 		$645K Buy
4,589
+1,916
+72% +$323K ﹤0.01% 886
2018
Q3 		$683K Buy
2,673
+462
+21% +$128K ﹤0.01% 1010
2018
Q2 		$564K Buy
+2,211
New +$547K ﹤0.01% 1102

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Los Angeles Capital Management's KPTI Position: Q3 2024 in Review

Los Angeles Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 23,601 shares — an estimated $307K sold.

Los Angeles Capital Management first reported a position in KPTI in Q2 2018 and held it in 13 quarters. The position peaked at $683K in Q3 2018. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Los Angeles Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Los Angeles Capital Management sold 23,601 Karyopharm Therapeutics shares in Q3 2024, an estimated $307K.
  • Los Angeles Capital Management first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 13 quarters.
  • Los Angeles Capital Management's Karyopharm Therapeutics position peaked at $683K in Q3 2018.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Los Angeles Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.